Pasithea Therapeutics Corp (KTTA) - Long-Term Liabilities to Capital

The development of neuropreparations at Pasithea Therapeutics (KTTA) is based on virtual modeling with synthesis and testing distributed across overseas cGMP centers, while the high cost of clinical trials and strict FDA oversight create a significant barrier to entry for competitors. This price chart illustrates the asset's dynamics, with a value of 0.00. Currently, Pasithea Therapeutics (KTTA) is systematically utilizing its available liquidity to fund research into antidepressants.

The deployment of software robots for neurotherapy analysis requires capital expenditures, which is reflected in the current long-term debt-to-equity ratio for Pasithea Therapeutics (KTTA). This metric compares liabilities with a maturity of over one year against shareholders' equity. The ratio is calculated by dividing long-term loans by the equity value. A sharp decline in this indicator may signal a rise in share prices rather than the repayment of loans. This allows for an assessment of the financial stability of Pasithea Therapeutics.